Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye test could spot Blindness-Causing diseases years earlier

NCT ID NCT07170683

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a special eye test called microperimetry to see if it can detect early signs of dry age-related macular degeneration and diabetic retinopathy. Researchers will measure how sensitive the central retina is to light and compare it with standard scans. The goal is to find changes before vision loss occurs, which could lead to better monitoring and future treatments. The study involves 200 participants, including healthy volunteers, and follows them for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to earlier detection of macular diseases, helping doctors monitor progression and potentially guide future treatments.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve patient outcomes, and the new test might not prove better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from the Medical Retina and Macular clinics of the Queen's Medical Centre. Healthy controls will be recruited from persons accompanying patients to the Eye Clinic, hospital and University staff. Healthy volunteers who are accompanying persons to the clinic will be approached after the patient participant has been approached.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

A. Patients Inclusion Criteria: * Adult age above 21 years old. * Signed informed consent * Visual acuity Log MAR 0.0 to 1.2 * Patients diagnosed with: * Geographic atrophy (AMD). * Diabetic without retinopathy, and minimal to moderate non-proliferative diabetic retinopathy (NPDR) with or without presence of macular oedema on optical coherence tomography (OCT) * Control group of age matched participants without any retinal disease, glaucoma or optic nerve disease in either eye Patients willing to attend follow-up MP examinations. (This does not apply to normal controls who only require one attendance). Exclusion Criteria * Moderate to severe cataract (over grade 2) or other cause of opaque optical media that will preclude adequate fundoscopy or MP assessment. * Previous treatments in the eye with intravitreal therapies of anti-VEGFs or steroids within the previous 6 months, or macular laser photocoagulation * Active vascular event in either eye any examination time. * Participants who are unable/unwilling to provide consent * Participants who are unable to read English fluently B. Normal Controls Inclusion Criteria * Normal controls will include persons who are not diabetic, and do not have glaucoma, any retinal or optic nerve disease. * Signed informed consent * Adult age above 21 years old. No upper age limit. * Visual acuity LogMAR \<0.2. * Controls should be willing to attend once only. Exclusion criteria * Moderate to severe cataract (over grade 2) or other cause of opaque optical media * Previous treatments in the particular eye with intravitreal therapies of anti-VEGFs or steroids within the previous 6 months, or macular laser photocoagulation * Active/previous vascular event in either eye e.g. retinal arterial or vein occlusion, ischaemic optic neuropathy, or glaucoma * Persons with diabetes * Participants who are unable to read English fluently * Participants who are unable/unwilling to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic retinopathy (DR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic retinopathy dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic retinopathy (DR) Dry AMD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nottingham University Hospitals NHS Trust

    Nottingham, Notts, NG7 2UH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.